Discover
CBIO
Crescent Biopharma, Inc.
17.08
2 x 13.14
2 x 21.79
bid
ask
-
0.92
5.11%
2 @ 04:00 PM
16.95 -0.13 (0.76%)
| Ytd | 44.01% | |
| 1y | 5.76% |
16.97
day range
18.52
8.72
52 week range
27.41
| Open | 18.00 | Prev Close | 18.00 | Low | 16.97 | High | 18.52 | Mkt Cap | 470.98M |
| Vol | 179.07K | Avg Vol | 315.55K | EPS | -5.88 | P/E | N/A | Forward P/E | -17.04 |
| Beta | 1.29 | Short Ratio | 0.19 | Inst. Own | 8.75% | Dividend | 15.94 | Div Yield | 792.92 |
| Ex Div Date | 01-13 | Earning | N/A | 50-d Avg | 19.49 | 200-d Avg | 14.47 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 25.77M | ||
| Research and Development Expense | 17.90M | ||
| Selling, General and Administrative Expense | 7.87M | ||
| Operating Income | -25.77M | ||
| Net Income | -23.28M | ||
| Net Income Common Stock | -23.28M | ||
| Net Income Common Stock (USD) | -23.28M | ||
| Consolidated Income | -23.28M | ||
| Earnings per Basic Share | -0.70 | ||
| Earnings per Basic Share (USD) | -0.70 | ||
| Earnings per Diluted Share | -0.70 | ||
| Earning Before Interest & Taxes (EBIT) | -23.28M | ||
| Earning Before Interest & Taxes (USD) | -23.28M | ||
| Weighted Average Shares | 30.40M | ||
| Weighted Average Shares Diluted | 30.40M | ||
| Balance Sheet | |||
| Cash and Equivalents | 189.27M | ||
| Cash and Equivalents (USD) | 189.27M | ||
| Current Assets | 195.56M | ||
| Property, Plant & Equipment Net | 2.30M | ||
| Total Assets | 199.13M | ||
| Debt Current | 453.00K | ||
| Total Debt | 1.54M | ||
| Current Liabilities | 14.19M | ||
| Debt Non-Current | 1.09M | ||
| Total Liabilities | 15.28M | ||
| Accumulated Retained Earnings (Deficit) | -195.09M | ||
| Shareholders Equity | 183.85M | ||
| Shareholders Equity (USD) | 183.85M | ||
| Assets Non-Current | 3.57M | ||
| Total Debt (USD) | 1.54M | ||
| Deferred Revenue | 3.12M | ||
| Liabilities Non-Current | 1.09M | ||
| Trade and Non-Trade Payables | 1.19M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 161.00K | ||
| Net Cash Flow from Financing | -6.94M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -24.03M | ||
| Capital Expenditure | -147.00K | ||
| Net Cash Flow - Business Acquisitions and Disposals | -8.00M | ||
| Net Cash Flow from Investing | -8.15M | ||
| Net Cash Flow from Operations | -8.94M | ||
| Share Based Compensation | 4.11M | ||